Health Care Cost Associated With Prostate Cancer, Androgen Deprivation Therapy and Bone Complications

Journal of Urology

Volumn 178, Issue 4, 2007, Pages 1423-1428

  Krupski, Tracey L ^a   Foley, Kathleen A ^b   Baser, Onur ^b   Long, Stacey ^b   Macarios, David ^c   Litwin, Mark S ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MEDSTAT GROUP   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bone; fractures; health care costs; hormone antagonists; prostatic neoplasms

Indexed keywords

ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; BONE METASTASIS; COMORBIDITY; FRACTURE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE DENSITY; BONE NEOPLASMS; COSTS AND COST ANALYSIS; FOLLOW-UP STUDIES; FRACTURES, SPONTANEOUS; GONADOTROPIN-RELEASING HORMONE; HEALTH CARE COSTS; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICARE; ORCHIECTOMY; OSTEOPOROSIS; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 34548515743     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.135     Document Type: Article

References (20)

1. Merrill R.M., Weed D.L., and Feuer E.J. The lifetime risk of developing prostate cancer in white and black men. Cancer Epidemiol Biomarkers Prev 6 (1997) 763
2. Han M., Partin A.W., Pound C.R., Epstein J.I., and Walsh P.C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555
3. Ward J.F., and Moul J.W. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2 (2005) 174
4. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781
5. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) S42
6. Krupski T.L., Saigal C.S., Hanley J., Schonlau M., and Litwin M.S. Patterns of care for men with prostate cancer after failure of primary treatment. Cancer 107 (2006) 258
7. Ray N.F., Chan J.K., Thamer M., and Melton III L.J. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12 (1997) 24
8. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373
9. Imbens G.W. An efficient method of moments estimator for discrete choice models with choice-based sampling. Econometrica 60 (1992) 1187
10. Falahati-Nini A., Riggs B.L., Atkinson E.J., O'Fallon W.M., Eastell R., and Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106 (2000) 1553
11. Daniell H.W., Dunn S.R., Ferguson D.W., Lomas G., Niazi Z., and Stratte P.T. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163 (2000) 181
12. Berruti A., Dogliotti L., Terrone C., Cerutti S., Isaia G., Tarabuzzi R., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167 (2002) 2361
13. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154
14. Zhou Z., Redaelli A., Johnell O., Willke R.J., and Massimini G. A retrospective analysis of health care costs for bone fractures in women with early-stage breast carcinoma. Cancer 100 (2004) 507
15. Nair B., Wilt T., MacDonald R., and Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 1 (2002) CD003506
16. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol 173 (2005) 1572
17. Smith M.R., McGovern F.J., Zietman A.L., Fallon M.A., Hayden D.L., Schoenfeld D.A., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948
18. Diamond T.H., Winters J., Smith A., DeSouza P., Kersley J., Lynch W., et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 92 (2001) 1444
19. Holmes-Walker D.J., Woo H., Gurney H., Do V.T., and Chipps D.R. Maintaining bone health in patients with prostate cancer. Med J Aust 184 (2006) 176
20. Weinfurt K.P., Castel L.D., Li Y., Timbie J.W., Glendenning G.A., and Schulman K.A. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 42 (2004) 164